NeuroStar® Advanced Therapy Providers Offer Free TMS Consultations During National Depression Awareness Month
Depression currently impacts more than 16.1 million adults in the U.S.,1,2,3 but many do not seek treatment or are not helped by antidepressant medications. Antidepressant medications are often the first treatment patients turn to, but the reality is they aren’t a one-size-fits-all solution. There are currently 5.5 million adults with depression in the
NeuroStar is a non-invasive treatment for adults with Major Depressive Disorder (MDD) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.6,7 Neuronetics has more than 1,000 NeuroStar devices installed in doctors’ offices and hospitals in the
“Over the past few months, we’ve seen the depression rate rise along with patients in need. The pandemic has brought mental health conversations to the forefront, and it is imperative that we continue to educate patients about alternative treatment options for depression,” said
During these consultations, patients have the opportunity to learn more about NeuroStar from a healthcare professional and collaborate with the provider to determine if NeuroStar Advanced Therapy could be an appropriate next step for the treatment of their depression. In addition to free consults, many providers also offer free depression screenings. Visit NeuroStar’s Find a Doctor page and call a local provider to learn more about available services.
As part of its National Depression Awareness Month efforts,
To join the conversation during National Depression Awareness Month and to help destigmatize depression, follow NeuroStar on Facebook, Instagram and Twitter, and access additional resources at www.NeuroStar.com/DepressionAwareness. For more information about NeuroStar, visit www.NeuroStar.com.
About Neuronetics
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, and the #1 choice of TMS doctors for patients with Major Depressive Disorder (MDD). Widely available across the United States, NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare.
In the U.S., NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance.
In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar System were 4.2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0.02; odds ratio = 4.05).8 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of
Media Contact:
610-455-2779
mdominick@vaultcommunications.com
1 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed
2 Kessler RC, et al. (2003), JAMA
3 Gaynes BN, et al. (2008),
4 Ettman CK, et al. (2020) JAMA Network Open
5
6 Post A, et al. (2001),
7 Liston C, et al. (2014), Biol Psychiatry
8
Source: Neuronetics